WisdomTree International MidCap Dividend Fund DIM
Set alert
85.60 USD -0.48 -0.55%
As of Oct 30, 3:49 PM ET
85.43 Day range 85.60
75.63 52-week range 90.40
- YTD
- +6.25%
- 1 year
- +10.66%
- Open
- 85.74
- Prev close
- 86.07
- Mkt cap
- 159.14M
- Vol
- 1.34K
- Avg vol
- 3.58K
- EPS
- 5.96
- P/E
- 14.37
- Div yield
- 0.00%
More statistics
- Low
- 85.43
- High
- 85.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 63.06
- 200-d avg
- 63.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 11.57
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 63.06
- 200-day average
- 63.00
About WisdomTree International MidCap Dividend Fund
The fund normally invests at least 95% of its total assets (exclusive of collateral held from securities lending) in constituent securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such constituent securities. The index is a fundamentally weighted index that is comprised of the mid-capitalization segment of the dividend-paying market in the industrialized world outside the U.S. and Canada. The fund is non-diversified.
News
- A Deeper Look At Our International Dividend Index Rebalance
- 10 Mid-Cap ETFs to Buy for Next Decade
- Nine-month Figures For 2019: Sartorius Stedim Biotech Reports Double-digit Sales Growth
- Nine-Month Figures for 2018: Sartorius Stedim Biotech Continues to Grow by Double Digits
- Business Figures for the First Half of 2018: Sartorius Stedim Biotech Records Double-Digit Growth in Sales and Profit
- First-Quarter Figures: Sartorius Stedim Biotech off to a Dynamic Start into 2018
- Preliminary Results for 2017: Sartorius Stedim Biotech Grows in Revenue and Earnings – Positive Outlook for 2018
- Sartorius Stedim Biotech: Growth dynamics temporarily dampened; continued strong mid-term perspectives
- Sartorius Stedim Biotech S.A.: 2017 First-Half Figures
- First-Quarter Figures: Sartorius Stedim Biotech Off to a Good Start in 2017
Your note
Sign in to keep a note on DIM — it syncs with the Stock Master app.